Key result
A novel prothrombin-based APC-R assay demonstrated 100% sensitivity and specificity for detecting Factor V Leiden mutations at a cutoff ratio of 2.5.
Why the study?
Does a novel prothrombin-based APC-R assay improve the distinction of Factor V wild-type and Factor V Leiden compared to the aPTT-based method in patients undergoing thrombophilia screening?
Observational (n=703)
Does a novel prothrombin-based APC-R assay improve the distinction of Factor V wild-type and Factor V Leiden compared to the aPTT-based method in patients undergoing thrombophilia screening?
A novel prothrombin-based APC-R assay provides 100% sensitivity and specificity for detecting Factor V Leiden mutations without interference from common coagulation variables.
Answers are grounded in this paper and cite their sources.
May support prothrombin-based APC-R testing in thrombophilia screening; leaves open prospective validation versus aPTT-based methods.
A new prothrombin-based activated protein C resistance (APC-R) test is described. In this method, the patient sample is prediluted in a plasma depleted of factor V (FV). A reagent containing APC and a specific activator of FV is added. After an incubation period, clotting is initiated by the addition of the FV-dependent prothrombin activator Noscarin. We analyzed 703 samples from patients undergoing thrombophilia screening. By using a predefined cutoff ratio of 2.5, 100% sensitivity and specificity for the detection of a factor V Leiden (FVL) mutation was found. With a cutoff ratio of 1.2, a complete but narrow distinction of FVL heterozygous (n = 192) and FVL homozygous samples (n = 27) was determined. No interference by the international normalized ratio, activated partial thromboplastin time (aPTT), protein S activity, fibrinogen and factor VIII (FVIII) levels, or lupus anticoagulant ratio was detected. The new prothrombin-based APC-R assay provides improved distinction of FV wild-type and FVL carriers compared with the aPTT-based method. By the use of an FV-dependent prothrombin activator, the assay is not influenced by FVIII concentration or lupus anticoagulants.
No takes yet. Share an insight, caveat, or question.
Wilmer et al. (2004) conducted an observational in Thrombophilia (n=703). Prothrombin-based activated protein C resistance (APC-R) test vs. aPTT-based method was evaluated on Detection of Factor V Leiden (FVL) mutation. A novel prothrombin-based APC-R assay demonstrated 100% sensitivity and specificity for detecting Factor V Leiden mutations at a cutoff ratio of 2.5.
Synapse has enriched 10 related papers. Consider them for comparative context: